Parkinson's Disease: The Epidemiology, Risk Factors, Molecular Pathogenesis, Prevention, and Therapy

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder with a growing global burden. Current pharmacological therapies remain limited to symptomatic management, owning to an incomplete understanding of the mechanisms driving α‑synuclein aggregation and disease progression. This review provides an integrated overview of PD across epidemiological, etiological, pathophysiological, and clinical dimensions. It emphasizes established and emerging risk factors, including environmental toxins, lifestyle variables, and gut microbiota dysbiosis and delineates how peripheral–central pathways such as the gut–brain, erythrocyte–brain, and kidney–brain axes contribute to PD pathogenesis. At the molecular level, we explore key disruptions including proteostatic failure, aberrant phase separation, oxidative stress, neuroinflammation, synaptic dysfunction, iron dyshomeostasis, and impaired cholesterol metabolism. These encompass microbiome‑targeted interventions and blood-based approaches. We further evaluate a spectrum of management strategies ranging from primary prevention and biomarker‑guided early detection to innovative experimental treatments such as cellular therapies, transfusion‑based modalities, and microbial modulation. By integrating recent advances in systemic pathophysiology with translational perspectives, this review highlights how molecular and cellular dysregulations underlie clinical phenotypes. Finally, we discuss promising biomarkers derived from microbial, inflammatory, and erythrocyte pathways that may facilitate early diagnosis and the development of disease‑modifying therapies.

Keywords

α‑synuclein / blood transfusion / gut–brain axis / protein aggregation / Parkinson's disease

References

[1] J. Q. Trojanowski, M. Goedert, T. Iwatsubo, et al., “Fatal Attractions: Abnormal Protein Aggregation and Neuron Death in Parkinson's Disease and Lewy Body Dementia,” Cell Death and Differentiation 5, no. 10 (1998): 832–837.

[2] H. Braak, K. Del Tredici, U. Rüb, et al., “Staging of Brain Pathology Related to Sporadic Parkinson's Disease,” Neurobiology of Aging 24, no. 2 (2003): 197–211.

[3] B. Mollenhauer, “Prediagnostic Presentation of Parkinson's Disease in Primary Care: A Case-control Study,” Movement Disorders 30, no. 6 (2015): 787.

[4] A. Mhanna, S. Maya, A. Ghassa, et al., “The Non-Motor Prodromal Symptoms of Parkinson's Disease: A Review,” Scientific Journal of King Faisal University: Basic and Applied Sciences 25, no. 1 (2024): 25–29.

[5] M. Relja, “Depression and Pain in Parkinson's Disease,” Acta Clin Croat 52, no. 1 (2013): 37.

[6] A. Tarakad, “Motor Features of Parkinson's Disease,” Neurologic Clinics 43, no. 2 (2025): 279–289.

[7] Y. Bang, J. Lim, and H. J. Choi, “Recent Advances in the Pathology of Prodromal Non-motor Symptoms Olfactory Deficit and Depression in Parkinson's Disease: Clues to Early Diagnosis and Effective Treatment,” Arch Pharm Res 44, no. 6 (2021): 588–604.

[8] L. F. Q. Fernandes, R. C. De Medeiros Dantas, M. C. M. Araújo, et al., “Non-motor Clinical Manifestations of Parkinson's Disease and Its Relevance in Early Diagnosis,” Sao Paulo Med J 139, no. 1 (2021): 1–250.

[9] X. Y. Du, X. X. Xie, and R. T. Liu, “The Role of α-Synuclein Oligomers in Parkinson's Disease,” International Journal of Molecular Sciences 21, no. 22 (2020): 8645.

[10] C. Wang, C. Y. Lau, F. Ma, et al., “Genome-wide Screen Identifies Curli Amyloid Fibril as a Bacterial Component Promoting Host Neurodegeneration,” PNAS 118, no. 34 (2021): e2106504118.

[11] S. Zhang, R. Zhu, B. Pan, et al., “Post-translational Modifications of Soluble α-synuclein Regulate the Amplification of Pathological α-synuclein,” Nature Neuroscience 26, no. 2 (2023): 213–225.

[12] K. Yao and Y.-F. Zhao, “Aging Modulates Microglia Phenotypes in Neuroinflammation of MPTP-PD Mice,” Experimental Gerontology 111 (2018): 86–93.

[13] Y. Bai, J. Zhou, H. Zhu, et al., “Isoliquiritigenin Inhibits Microglia-mediated Neuroinflammation in Models of Parkinson's Disease via JNK/AKT/NFκB Signaling Pathway,” Phytotherapy Research 37, no. 3 (2023): 848–859.

[14] Y. F. Zhao, Z. Qiong, J. F. Zhang, et al., “The Synergy of Aging and LPS Exposure in a Mouse Model of Parkinson's Disease,” Aging Dis 9, no. 5 (2018): 785–797.

[15] F. X. Zhang and R. S. Xu, “Juglanin Ameliorates LPS-induced Neuroinflammation in Animal Models of Parkinson's Disease and Cell Culture via Inactivating TLR4/NF-κB Pathway,” Biomedicine & Pharmacotherapy 97 (2018): 1011–1019.

[16] J. Zhou, Y. Deng, F. Li, et al., “Icariside II Attenuates Lipopolysaccharide-induced Neuroinflammation Through Inhibiting TLR4/MyD88/NF-κB Pathway in Rats,” Biomedicine & Pharmacotherapy 111 (2019): 315–324.

[17] T. Pan, Q. Xiao, and H.-J. Fan, “Wuzi Yanzong Pill Relieves MPTP-induced Motor Dysfunction and Neuron Loss by Inhibiting NLRP3 Inflammasome-mediated Neuroinflammation,” Metabolic Brain Disease 38, no. 7 (2023): 2211–2222.

[18] F. Magrinelli, A. Picelli, P. Tocco, et al., “Pathophysiology of Motor Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and Rehabilitation,” Parkinsons Dis 2016 (2016): 9832839.

[19] H. Braak, R. A. de Vos, J. Bohl, et al., “Gastric Alpha-synuclein Immunoreactive Inclusions in Meissner's and Auerbach's Plexuses in Cases Staged for Parkinson's Disease-related Brain Pathology,” Neuroscience Letters 396, no. 1 (2006): 67–72.

[20] T. Lebouvier, T. Chaumette, S. Paillusson, et al., “The Second Brain and Parkinson's Disease,” European Journal of Neuroscience 30, no. 5 (2009): 735–741.

[21] J. Xiang, J. Tang, F. Kang, et al., “Gut-induced Alpha-Synuclein and Tau Propagation Initiate Parkinson's and Alzheimer's Disease co-pathology and Behavior Impairments,” Neuron 112, no. 21 (2024): 3585–3601. e5.

[22] T. R. Sampson, J. W. Debelius, T. Thron, et al., “Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease,” Cell 167, no. 6 (2016): 1469–1480. e12.

[23] R. Chandra, A. Sokratian, K. R. Chavez, et al., “Gut Mucosal Cells Transfer α-synuclein to the Vagus Nerve,” JCI Insight 8, no. 23 (2023): e172192.

[24] L. Yang, R. Zhou, Y. Tong, et al., “Neuroprotection by Dihydrotestosterone in LPS-induced Neuroinflammation,” Neurobiology of Disease 140 (2020): 104814.

[25] Z. D. Wallen, M. Appah, M. N. Dean, et al., “Characterizing Dysbiosis of Gut Microbiome in PD: Evidence for Overabundance of Opportunistic Pathogens,” NPJ Parkinsons Dis 6 (2020): 11.

[26] E. H. Ahn, S. S. Kang, X. Liu, et al., “Initiation of Parkinson's Disease From Gut to Brain by δ-secretase,” Cell Research 30, no. 1 (2020): 70–87.

[27] Z. Zhang, S. S. Kang, X. Liu, et al., “Asparagine Endopeptidase Cleaves α-synuclein and Mediates Pathologic Activities in Parkinson's disease,” Nature structural & molecular biology 24, no. 8 (2017): 632–642.

[28] J. Matsumoto, T. Stewart, L. Sheng, et al., “Transmission of α-synuclein-containing Erythrocyte-derived Extracellular Vesicles Across the Blood-brain Barrier via Adsorptive Mediated Transcytosis: Another Mechanism for Initiation and Progression of Parkinson's Disease?,” Acta Neuropathologica Communications 5, no. 1 (2017): 71.

[29] Z. Yu, G. Liu, Y. Li, et al., “Erythrocytic α-Synuclein Species for Parkinson's Disease Diagnosis and the Correlations with Clinical Characteristics,” Frontiers in Aging Neuroscience 14 (2022): 827493.

[30] L. Sheng, T. Stewart, D. Yang, et al., “Erythrocytic α-synuclein Contained in Microvesicles Regulates Astrocytic Glutamate Homeostasis: A New Perspective on Parkinson's Disease Pathogenesis,” Acta Neuropathologica Communications 8, no. 1 (2020): 102.

[31] J. Lamontagne-Proulx, I. St-Amour, R. Labib, et al., “Portrait of Blood-derived Extracellular Vesicles in Patients With Parkinson's Disease,” Neurobiology of Disease 124 (2019): 163–175.

[32] Q. Yan, M. Liu, Y. Xie, et al., “Kidney-brain Axis in the Pathogenesis of Cognitive Impairment,” Neurobiology of Disease 200 (2024): 106626.

[33] J. Meléndez-Flores and I. Estrada-Bellmann, “Linking Chronic Kidney Disease and Parkinson's Disease: A Literature Review,” Metabolic Brain Disease 36, no. 1 (2020): 1–12.

[34] M. Wen, Y. Geng, Y. Liu, et al., “The Mechanisms of White Matter Injury and Immune System Crosstalk in Promoting the Progression of Parkinson's Disease: A Narrative Review,” Frontiers in Aging Neuroscience 16 (2024): 1345918.

[35] Institute for Health Metrics and Evaluation. GBD Results Tool. Institute for Health Metrics and Evaluation. Updated 2025. Accessed October 27, 2025. https://vizhub.healthdata.org/gbd-results/.

[36] World Health Organization. Parkinson Disease. World Health Organization. Updated August 9, 2023. Accessed October 7, 2025 https://www.who.int/news-room/fact-sheets/detail/parkinson-disease.

[37] World Health Organization. Launch of WHO's Parkinson Disease Technical Brief. World Health Organization. Updated June 14, 2022. Accessed October 7, 2025 https://www.who.int/news/item/14-06-2022-launch-of-who-s-parkinson-disease-technical-brief.

[38] K. Maqsood, M. Fatima, H. Naveed, et al., “Global, Regional, and National Burden of Parkinson's Disease From 1990–2023: An Analysis of Trends, Inequalities, and Future Projections,” Medrxiv (2025), https://doi.org/10.1101/2025.10.22.25338533.

[39] G. M. Pereira, D. Teixeira-Dos-Santos, N. M. Soares, et al., “A Systematic Review and Meta-analysis of the Prevalence of Parkinson's Disease in Lower to Upper-middle-income Countries,” NPJ Parkinsons Dis 10, no. 1 (2024): 181.

[40] Y. Luo, L. Qiao, M. Li, et al., “Global, Regional, National Epidemiology and Trends of Parkinson's Disease From 1990 to 2021: Findings From the Global Burden of Disease Study 2021,” Frontiers in Aging Neuroscience 16 (2025): 1498756.

[41] A. Zirra, S. C. Rao, J. Bestwick, et al., “Gender Differences in the Prevalence of Parkinson's Disease,” Mov Disord Clin Pract 10, no. 1 (2023): 86–93.

[42] D. Su, Y. Cui, C. He, et al., “Projections for Prevalence of Parkinson's Disease and Its Driving Factors in 195 Countries and territories to 2050: Modelling Study of Global Burden of Disease Study 2021,” Bmj 388 (2025): e080952.

[43] A. Diem-Zangerl, K. Seppi, G. K. Wenning, et al., “Mortality in Parkinson's Disease: A 20-year Follow-up Study,” Movement Disorders 24, no. 6 (2009): 819–825.

[44] M. Coelho and J. J. Ferreira, “Late-stage Parkinson Disease,” Nature Reviews Neurology 8, no. 8 (2012): 435–442.

[45] E. Noyes, A. H. Rajput, M. Kim, et al., “Increased Survival in Contemporary Parkinson's Disease: A 47-Year Autopsy Study,” Neuroepidemiology 59, no. 5 (2025): 517–524.

[46] A. Rajput, K. P. Offord, C. M. Beard, et al., “Epidemiology of Parkinsonism: Incidence, Classification, and Mortality,” Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society 16, no. 3 (1984): 278–282.

[47] Z. Ou, J. Pan, S. Tang, et al., “Global Trends in the Incidence, Prevalence, and Years Lived with Disability of Parkinson's Disease in 204 Countries/Territories from 1990 to 2019,” Front Public Health 9 (2021): 776847.

[48] Q. Q. Zhong and F. Zhu, “Trends in Prevalence Cases and Disability-Adjusted Life-Years of Parkinson's Disease: Findings From the Global Burden of Disease Study 2019,” Neuroepidemiology 56, no. 4 (2022): 261–270.

[49] H. Chen, “Are We Ready for a Potential Increase in Parkinson Incidence?,” JAMA Neurology 73, no. 8 (2016): 919–921.

[50] H. H. Liou, C. Y. Wu, Y. H. Chiu, et al., “Natural History and Effectiveness of Early Detection of Parkinson's Disease: Results From Two Community-based Programmes in Taiwan (KCIS no. 11),” Journal of Evaluation in Clinical Practice 14, no. 2 (2008): 198–202.

[51] J. Zhang, Y. Fan, H. Liang, et al., “Global, Regional and National Temporal Trends in Parkinson's Disease Incidence, Disability-adjusted Life Year Rates in Middle-aged and Older Adults: A Cross-national Inequality Analysis and Bayesian Age-period-cohort Analysis Based on the Global Burden of Disease 2021,” Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 46, no. 4 (2025): 1647–1660.

[52] D. Marinova and M. Danovska, “The Non-motor Symptoms–challenge in Diagnosis of Parkinson's Disease,” Journal of IMAB 26, no. 4 (2020): 3469–3474.

[53] S. De Jesus, A. Daya, L. Blumberger, et al., “Prevalence of Late-Stage Parkinson's Disease in the US Healthcare System: Insights From TriNetX,” Movement Disorders 39, no. 9 (2024): 1592–1601.

[54] H. G. Seo, S. J. Byun, B. M. Oh, et al., “Ten-Year Relative Survival from the Diagnosis of Parkinson's Disease: A Nationwide Database Study,” Journal of the American Medical Directors Association 22, no. 8 (2021): 1757–1761.

[55] J. Horne, “A Continuum of Care Model for Comprehensive Chronic Disease Management: The Parkinson's Wellbeing Program,” International Journal of Integrated Care 14, no. 9 (2014).

[56] S. Peng, P. Liu, X. Wang, et al., “Global, Regional and National Burden of Parkinson's Disease in People Over 55 Years of Age: A Systematic Analysis of the Global Burden of Disease Study, 1991–2021,” BMC Neurology [Electronic Resource] 25, no. 1 (2025): 178.

[57] Y. Hou, X. Dan, and M. Babbar, “Ageing as a Risk Factor for Neurodegenerative Disease,” Nature Reviews Neurology 15, no. 10 (2019): 565–581.

[58] M. P. Giannoccaro, C. La Morgia, and G. Rizzo, “Mitochondrial DNA and Primary Mitochondrial Dysfunction in Parkinson's Disease,” Movement Disorders 32, no. 3 (2017): 346–363.

[59] S. Moradi Vastegani, A. Nasrolahi, and S. Ghaderi, “Mitochondrial Dysfunction and Parkinson's Disease: Pathogenesis and Therapeutic Strategies,” Neurochemical Research 48, no. 8 (2023): 2285–2308.

[60] S. R. Subramaniam and M. F. Chesselet, “Mitochondrial Dysfunction and Oxidative Stress in Parkinson's Disease,” Progress in Neurobiology 106-107 (2013): 17–32.

[61] W. J. Geldenhuys, S. A. Benkovic, L. Lin, et al., “MitoNEET (CISD1) Knockout Mice Show Signs of Striatal Mitochondrial Dysfunction and a Parkinson's Disease Phenotype,” Acs Chemical Neuroscience 8, no. 12 (2017): 2759–2765.

[62] M. S. Hipp, P. Kasturi, and F. U. Hartl, “The Proteostasis Network and Its Decline in Ageing,” Nature Reviews Molecular Cell Biology 20, no. 7 (2019): 421–435.

[63] K. Yao and Y. F. Zhao, “Aging Modulates Microglia Phenotypes in Neuroinflammation of MPTP-PD Mice,” Experimental Gerontology 111 (2018): 86–93.

[64] S. Sulisthio, A. Momole, and S. Jehosua, “Role of Proinflammatory Biomarkers in Parkinson's Disease With Non-motor Symptoms: A Systematic Review and Meta-analysis,” Romanian Journal of Neurology 23, no. 2 (2024): 221–228.

[65] X. Tang, P. Gonzalez-Latapi, C. Marras, et al., “Epigenetic Clock Acceleration Is Linked to Age at Onset of Parkinson's Disease,” Movement Disorders 37, no. 9 (2022): 1831–1840.

[66] L. Baldelli, C. Pirazzini, L. Sambati, et al., “Epigenetic Clocks Suggest Accelerated Aging in Patients With Isolated REM Sleep Behavior Disorder,” Npj Parkinson's Disease 9, no. 1 (2023): 48.

[67] U. Ganguly, S. Singh, S. Pal, et al., “Alpha-Synuclein as a Biomarker of Parkinson's Disease: Good, but Not Good Enough,” Frontiers in Aging Neuroscience 13 (2021): 702639.

[68] E. Rymbai, D. Sugumar, A. Chakkittukandiyil, et al., “The Identification of Cianidanol as a Selective Estrogen Receptor Beta Agonist and Evaluation of Its Neuroprotective Effects on Parkinson's disease Models,” Life Sciences 333 (2023): 122144.

[69] C. Cattaneo and J. Pagonabarraga, “Sex Differences in Parkinson's Disease: A Narrative Review,” Neurol Ther 14, no. 1 (2025): 57–70.

[70] K. M. Smith and N. Dahodwala, “Sex Differences in Parkinson's Disease and Other Movement Disorders,” Experimental Neurology 259 (2014): 44–56.

[71] R. Bovenzi, G. M. Sancesario, M. Conti, et al., “Sex Hormones Differentially Contribute to Parkinson Disease in Males: A Multimodal Biomarker Study,” European Journal of Neurology 30, no. 7 (2023): 1983–1990.

[72] G. Barreto, M. F. Á. Rodríguez, R. Cabezas, et al., “Sex Differences in Parkinson's Disease: Features on Clinical Symptoms, Treatment Outcome, Sexual Hormones and Genetics,” Frontiers in Neuroendocrinology 50 (2017): 18–30.

[73] M. Morissette, T. Paolo, and N. Litim, “Neuroactive Gonadal Drugs for Neuroprotection in Male and Female Models of Parkinson's disease,” Neuroscience and Biobehavioral Reviews 67 (2016): 79–88.

[74] S. L. Schaffner, K. N. Tosefsky, A. M. Inskter, et al., “Sex and Gender Differences in the Molecular Etiology of Parkinson's Disease: Considerations for Study Design and Data Analysis,” Biology of Sex Differences 16, no. 1 (2025): 7.

[75] M. Bourque, J. Lamontagne-Proulx, A. Isenbrandt, et al., “Effect of Sex and Gonadectomy on Brain MPTP Toxicity and Response to Dutasteride Treatment in Mice,” Neuropharmacology 201 (2021): 108784.

[76] B. Garavaglia, M. Picillo, P. Barone, et al., “The Relevance of Gender in Parkinson's Disease: A Review,” Journal of Neurology 264, no. 8 (2017): 1583–1607.

[77] J. O. Day and S. Mullin, “The Genetics of Parkinson's Disease and Implications for Clinical Practice,” Genes 12, no. 7 (2021): 1006.

[78] M. A. Nalls, C. Blauwendraat, C. L. Vallerga, et al., “Identification of Novel Risk Loci, Causal Insights, and Heritable Risk for Parkinson's disease: A Meta-analysis of Genome-wide Association Studies,” Lancet Neurology 18, no. 12 (2019): 1091–1102.

[79] A. Westenberger, N. Brüggemann, and C. Klein, “Genetics of Parkinson's Disease: From Causes to Treatment,” Cold Spring Harbor Perspectives in Medicine 15, no. 7 (2025): a041774.

[80] M. L. Arotcarena, M. Teil, and B. Dehay, “Autophagy in Synucleinopathy: The Overwhelmed and Defective Machinery,” Cells 8, no. 6 (2019): 565.

[81] W. Satake, Y. Nakabayashi, I. Mizuta, et al., “Genome-wide Association Study Identifies Common Variants at Four Loci as Genetic Risk Factors for Parkinson's Disease,” Nature Genetics 41, no. 12 (2009): 1303–1307.

[82] H. M. Gao and J. S. Hong, “Gene-environment Interactions: Key to Unraveling the Mystery of Parkinson's Disease,” Progress in Neurobiology 94, no. 1 (2011): 1–19.

[83] J. Simón-Sánchez, C. Schulte, J. M. Bras, et al., “Genome-wide Association Study Reveals Genetic Risk Underlying Parkinson's Disease,” Nature Genetics 41, no. 12 (2009): 1308–1312.

[84] R. Kumaran and M. R. Cookson, “Pathways to Parkinsonism Redux: Convergent Pathobiological Mechanisms in Genetics of Parkinson's Disease,” Human Molecular Genetics 24, no. R1 (2015): R32–44.

[85] K. C. Paul, M. Cockburn, Y. Gong, et al., “Agricultural Paraquat Dichloride Use and Parkinson's Disease in California's Central Valley,” International Journal of Epidemiology 53, no. 1 (2024): dyae004.

[86] R. Franco, S. Li, H. Rodriguez-Rocha, et al., “Molecular Mechanisms of Pesticide-induced Neurotoxicity: Relevance to Parkinson's Disease,” Chemico-Biological Interactions 188, no. 2 (2010): 289–300.

[87] H. H. Liou, R. C. Chen, Y. F. Tsai, et al., “Effects of Paraquat on the Substantia nigra of the Wistar Rats: Neurochemical, Histological, and Behavioral Studies,” Toxicology and Applied Pharmacology 137, no. 1 (1996): 34–41.

[88] C. Berry, C. La Vecchia, and P. Nicotera, “Paraquat and Parkinson's Disease,” Cell Death and Differentiation 17, no. 7 (2010): 1115–1125.

[89] C. M. Tanner, F. Kamel, G. W. Ross, et al., “Rotenone, Paraquat, and Parkinson's Disease,” Environmental Health Perspectives 119, no. 6 (2011): 866–872.

[90] L. Amaral, M. Martins, M. Côrte-Real, et al., “The Neurotoxicity of Pesticides: Implications for Parkinson's Disease,” Chemosphere 377 (2025): 144348.

[91] S. Pyatha, H. Kim, D. Lee, et al., “Association Between Heavy Metal Exposure and Parkinson's Disease: A Review of the Mechanisms Related to Oxidative Stress,” Antioxidants (Basel) 11, no. 12 (2022): 2467.

[92] M. A. Gonzalez-Alvarez, D. Hernandez-Bonilla, N. I. Plascencia-Alvarez, et al., “Environmental and Occupational Exposure to Metals (manganese, mercury, iron) and Parkinson's Disease in Low and Middle-income Countries: A Narrative Review,” Reviews on Environmental Health 37, no. 1 (2022): 1–11.

[93] T. C. Hunter, R. So, S. Antic, et al., “Long-term Exposure to Air Pollution and Incidence of Parkinson's Disease: A Danish Nationwide Administrative Cohort Study.” ISEE Conference Abstracts. 2023;2023(1).

[94] Y. J. Kang, H. Y. Tan, C. Y. Lee, et al., “An Air Particulate Pollutant Induces Neuroinflammation and Neurodegeneration in Human Brain Models,” Adv Sci (Weinh) 8, no. 21 (2021): e2101251.

[95] F. Liu, Y. Huang, F. Zhang, et al., “Macrophages Treated With Particulate Matter PM2.5 Induce Selective Neurotoxicity Through Glutaminase-mediated Glutamate Generation,” Journal of Neurochemistry 134, no. 2 (2015): 315–326.

[96] H. Bai, H. Gu, W. Zhou, et al., “PD-Like Pathogenesis Induced by Intestinal Exposure to Microplastics: An in Vivo Study of Animal Models to a Public Health Survey,” Journal of Hazardous Materials 486 (2025): 136974.

[97] A. Jeong, S. J. Park, E. J. Lee, et al., “Nanoplastics Exacerbate Parkinson's disease Symptoms in C. elegans and human Cells,” Journal of Hazardous Materials 465 (2024): 133289.

[98] C. Boulos, N. Yaghi, and R. El Hayeck, “Nutritional Risk Factors, Microbiota and Parkinson's Disease: What Is the Current Evidence?,” Nutrients 11, no. 8 (2019): 1896.

[99] G. Logroscino, X. Gao, H. Chen, et al., “Dietary Iron Intake and Risk of Parkinson's Disease,” American Journal of Epidemiology 168, no. 12 (2008): 1381–1388.

[100] E. Hantikainen, E. Roos, R. Bellocco, et al., “Dietary Fat Intake and Risk of Parkinson Disease: Results From the Swedish National March Cohort,” European Journal of Epidemiology 37, no. 6 (2022): 603–613.

[101] W. Jiang, C. Ju, H. Jiang, et al., “Dairy Foods Intake and Risk of Parkinson's Disease: A Dose-response Meta-analysis of Prospective Cohort Studies,” European Journal of Epidemiology 29, no. 9 (2014): 613–619.

[102] M. G. Weisskopf, E. O'Reilly, and H. Chen, “Plasma Urate and Risk of Parkinson's Disease,” American Journal of Epidemiology 166, no. 5 (2007): 561–567.

[103] H. K. Choi, S. Liu, and G. Curhan, “Intake of Purine-rich Foods, Protein, and Dairy Products and Relationship to Serum Levels of Uric Acid: The Third National Health and Nutrition Examination Survey,” Arthritis and Rheumatism 52, no. 1 (2005): 283–289.

[104] J. Zhao, Y. Peng, Z. Lin, et al., “Association Between Mediterranean Diet Adherence and Parkinson's Disease: A Systematic Review and Meta-analysis,” Journal of Nutrition, Health and Aging 29, no. 2 (2025): 100451.

[105] K. Sääksjärvi, P. Knekt, A. Lundqvist, et al., “A Cohort Study on Diet and the Risk of Parkinson's Disease: The Role of Food Groups and Diet Quality,” British Journal of Nutrition 109, no. 2 (2013): 329–337.

[106] M. C. L. Phillips, D. K. J. Murtagh, L. J. Gilbertson, et al., “Low-fat versus Ketogenic Diet in Parkinson's disease: A Pilot Randomized Controlled Trial,” Movement Disorders 33, no. 8 (2018): 1306–1314.

[107] R. J. Solch, J. O. Aigbogun, A. G. Voyiadjis, et al., “Mediterranean Diet Adherence, Gut Microbiota, and Alzheimer's or Parkinson's Disease Risk: A Systematic Review,” Journal of the Neurological Sciences 434 (2022): 120166.

[108] B. A. Seelarbokus, E. Menozzi, A. H. V. Schapira, et al., “Mediterranean Diet Adherence, Gut Microbiota and Parkinson's Disease: A Systematic Review,” Nutrients 16, no. 14 (2024): 2181.

[109] J. H. An, K. D. Han, J. H. Jung, et al., “Association of Physical Activity With the Risk of Parkinson's Disease in Depressive Disorder: A Nationwide Longitudinal Cohort Study,” Journal of Psychiatric Research 167 (2023): 93–99.

[110] A. Khan, J. Ezeugwa, and V. E. Ezeugwu, “A Systematic Review of the Associations Between Sedentary Behavior, Physical Inactivity, and Non-motor Symptoms of Parkinson's Disease,” PLoS ONE 19, no. 3 (2024): e0293382.

[111] C. Li, B. Ke, J. Chen, et al., “Systemic Inflammation and Risk of Parkinson's disease: A Prospective Cohort Study and Genetic Analysis,” Brain, Behavior, and Immunity 117 (2024): 447–455.

[112] W. Maetzler, I. Liepelt-Scarfone, P. Sulzer, et al., “Cognitive Impairment and Sedentary Behavior Predict Health-related Attrition in a Prospective Longitudinal Parkinson's disease Study,” Parkinsonism & Related Disorders 82 (2020): 37–43.

[113] J. Pérez-H, A. Chavarría, and P. Ugalde-Muñiz. “Is Chronic Systemic Inflammation a Determinant Factor in Developing Parkinson's Disease?” In: Dushanova J, Kozubski W, eds. “Mechanisms in Parkinson's Disease—Models and Treatments”.(InTech, 2016): 107–133.

[114] R. Rotondo, S. Proietti, M. Perluigi, et al., “Physical Activity and Neurotrophic Factors as Potential Drivers of Neuroplasticity in Parkinson's Disease: A Systematic Review and Meta-analysis,” Ageing Research Reviews 92 (2023): 102089.

[115] G. M. Petzinger, D. P. Holschneider, B. E. Fisher, et al., “The Effects of Exercise on Dopamine Neurotransmission in Parkinson's Disease: Targeting Neuroplasticity to Modulate Basal Ganglia Circuitry,” Brain Plast 1, no. 1 (2015): 29–39.

[116] W. Chen, D. Qiao, X. Liu, et al., “Treadmill Exercise Improves Motor Dysfunction and Hyperactivity of the Corticostriatal Glutamatergic Pathway in Rats With 6-OHDA-Induced Parkinson's Disease,” Neural Plasticity 2017 (2017): 2583910.

[117] K. Yaffe, J. Nettiksimmons, C. Tanner, et al., “Traumatic Brain Injury in Later Life Increases Risk for Parkinson Disease,” Annals of Neurology 77, no. 6 (2015): 987–995.

[118] M. Balabandian, M. Noori, B. Lak, et al., “Traumatic Brain Injury and Risk of Parkinson's Disease: A Meta-analysis,” Acta Neurologica Belgica 123, no. 4 (2023): 1225–1239.

[119] V. Delic, K. D. Beck, K. C. H. Pang, et al., “Biological Links Between Traumatic Brain Injury and Parkinson's Disease,” Acta Neuropathol Commun 8, no. 1 (2020): 45.

[120] H. L. Chiang and C. H. Lin, “Altered Gut Microbiome and Intestinal Pathology in Parkinson's Disease,” J Mov Disord 12, no. 2 (2019): 67–83.

[121] J. Sobral, N. Empadinhas, A. R. Esteves, et al., “Impact of Nutrition on the Gut Microbiota: Implications for Parkinson's Disease,” Nutrition Reviews 83, no. 4 (2025): 713–727.

[122] S. Mazmanian, “The Gut Microbiome Connection to Parkinson's Disease,” The FASEB Journal 32, no. 1 (2018): 1014.

[123] F. Scheperjans, V. Aho, P. A. Pereira, et al., “Gut Microbiota Are Related to Parkinson's Disease and Clinical Phenotype,” Movement Disorders 30, no. 3 (2015): 350–358.

[124] A. Heintz-Buschart, U. Pandey, T. Wicke, et al., “The Nasal and Gut Microbiome in Parkinson's Disease and Idiopathic Rapid Eye Movement Sleep Behavior Disorder,” Movement Disorders 33, no. 1 (2018): 88–98.

[125] C. H. Hawkes, K. D. Tredici, and H. Braak, “Parkinson's Disease: A Dual-hit Hypothesis,” Neuropathology & Applied Neurobiology 33, no. 6 (2010): 599–614.

[126] T. R. Sampson, J. W. Debelius, T. Thron, et al., “Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease,” Cell 167, no. 6 (2016): 1469–1480. e12.

[127] B. L. Copple and T. Li, “Pharmacology of Bile Acid Receptors: Evolution of Bile Acids From Simple Detergents to Complex Signaling Molecules,” Pharmacological Research 104 (2016): 9–21.

[128] J. S. Loh, W. Q. Mak, L. K. S. Tan, et al., “Microbiota-gut-brain Axis and Its Therapeutic Applications in Neurodegenerative Diseases,” Signal Transduct Target Ther 9, no. 1 (2024): 37.

[129] X. Zhang, B. Tang, and J. Guo, “Parkinson's Disease and Gut Microbiota: From Clinical to Mechanistic and Therapeutic Studies,” Transl Neurodegener 12, no. 1 (2023): 59.

[130] M. Villumsen, S. Aznar, B. Pakkenberg, et al., “Inflammatory Bowel Disease Increases the Risk of Parkinson's Disease: A Danish Nationwide Cohort Study 1977–2014,” Gut 68, no. 1 (2019): 18–24.

[131] G. H. Kim, Y. C. Lee, T. J. Kim, et al., “Risk of Neurodegenerative Diseases in Patients With Inflammatory Bowel Disease: A Nationwide Population-based Cohort Study,” J Crohns Colitis 16, no. 3 (2022): 436–443.

[132] M. H. Seo, D. Kwon, S.-H. Kim, et al., “Association Between Decreased SGK1 and Increased Intestinal α-Synuclein in an MPTP Mouse Model of Parkinson's Disease,” International Journal of Molecular Sciences 24, no. 22 (2023): 16408.

[133] S. Kim, S. H. Kwon, T. I. Kam, et al., “Transneuronal Propagation of Pathologic α-Synuclein From the Gut to the Brain Models Parkinson's Disease,” Neuron 103, no. 4 (2019): 627–641. e7.

[134] Z. Wu, Y. Xia, Z. Wang, et al., “C/EBPβ/δ-secretase Signaling Mediates Parkinson's Disease Pathogenesis via Regulating Transcription and Proteolytic Cleavage of α-synuclein and MAOB,” Molecular Psychiatry 26, no. 2 (2021): 568–585.

[135] L. Li, V. L. Dawson, and T. M. Dawson, “Gastrointestinal Tract Cleavage of α-synuclein by Asparaginyl Endopeptidase Leads to Parkinson's Disease,” Neuron 112, no. 21 (2024): 3516–3518.

[136] G. Liu, Z. Yu, L. Gao, et al., “Erythrocytic Alpha-synuclein in Early Parkinson's Disease: A 3-year Longitudinal Study,” Parkinsonism & Related Disorders 104 (2022): 44–48.

[137] S. Abraham, C. C. Soundararajan, S. Vivekanandhan, et al., “Erythrocyte Antioxidant Enzymes in Parkinson's Disease,” Indian Journal of Medical Research 121, no. 2 (2005): 111–115.

[138] L. Fatkullina, E. Molochkina, A. Kozachenko, et al., “Structural and Functional State of Erythrocyte Membranes in Mice at Different Stages of Experimental Parkinson's Disease Induced by Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP),” Bulletin of Experimental Biology and Medicine 162, no. 5 (2017): 597–601.

[139] S. X. Jianjun and M. Li, “MicroRNA-181a–2–3p Shuttled by Mesenchymal Stem Cell-secreted Extracellular Vesicles Inhibits Oxidative Stress in Parkinson's disease by Inhibiting EGR1 and NOX4,” Cell Death Discov 8, no. 1 (2022): 33.

[140] X. Yang, Y. Ma, H. Xie, et al., “Extracellular Vesicles in the Treatment of Parkinson's Disease: A Review,” Current Medicinal Chemistry 28, no. 31 (2021): 6375–6394.

[141] L. Leggio, F. L'Episcopo, and A. Magrì, “Small Extracellular Vesicles Secreted by Nigrostriatal Astrocytes Rescue Cell Death and Preserve Mitochondrial Function in Parkinson's Disease,” Adv Healthc Mater 11, no. 20 (2022): e2201203.

[142] Y. Yang, X. Nie, Y. Wang, et al., “Evolving Insights Into Erythrocytes in Synucleinopathies,” Trends in Neuroscience (Tins) 47, no. 9 (2024): 693–707.

[143] N. B. Campomayor, H. J. Kim, and M. Kim, “Pro-Oxidative and Inflammatory Actions of Extracellular Hemoglobin and Heme: Molecular Events and Implications for Alzheimer's and Parkinson Disease,” Biomol Ther (Seoul) 33, no. 2 (2025): 235–248.

[144] K. Wang, J. Shen, and Y. Xu, “An Update on Peripheral Blood Extracellular Vesicles as Biomarkers for Parkinson's Disease Diagnosis,” Neuroscience 511 (2022): 131–146.

[145] G. E. Nam, N. H. Kim, K. Han, et al., “Chronic Renal Dysfunction, Proteinuria, and Risk of Parkinson's Disease in the Elderly,” Movement Disorders 34, no. 8 (2019): 1184–1191.

[146] I. K. Wang, C. L. Lin, Y. Y. Wu, et al., “Increased Risk of Parkinson's Disease in Patients With End-stage Renal Disease: A Retrospective Cohort Study,” Neuroepidemiology 42, no. 4 (2014): 204–210.

[147] Y. Qu, Q. X. Qin, D. L. Wang, et al., “Estimated Glomerular Filtration Rate Is a Biomarker of Cognitive Impairment in Parkinson's Disease,” Frontiers in Aging Neuroscience 15 (2023): 1130833.

[148] G. Yang, L. Z. Wang, R. Zhang, et al., “Study on the Correlation Between Blood Urea Nitrogen, Creatinine Level, Proteinuria and Parkinson's Disease,” Neurology India 71, no. 6 (2023): 1217–1221.

[149] X. Yuan, S. Nie, Y. Yang, et al., “Propagation of Pathologic α-synuclein From Kidney to Brain May Contribute to Parkinson's Disease,” Nature Neuroscience 28, no. 3 (2025): 577–588.

[150] D. Cui, P. Gu, Y. Wang, et al., “Analysis of Serum and Urine β₂-microglobulin in Patients With Parkinson Disease,” Clinical Focus 22, no. 17 (2007): 1233–1235.

[151] J. D. Meléndez-Flores, A. C. Cavazos-Benítez, and I. Estrada-Bellmann, “Microalbuminuria as a Potential Biomarker for Parkinson's Disease Severity: A Hypothesis,” Medical Hypotheses 149 (2021): 110510.

[152] S. D. Skaper, P. Giusti, and L. Facci, “Microglia and Mast Cells: Two Tracks on the Road to Neuroinflammation,” Faseb Journal 26, no. 8 (2012): 3103–3117.

[153] S. H. Yoon, C. Y. Kim, E. Lee, et al., “Microglial NLRP3-gasdermin D Activation Impairs Blood-brain Barrier Integrity Through Interleukin-1β-independent Neutrophil Chemotaxis Upon Peripheral Inflammation in Mice,” Nature Communications 16, no. 1 (2025): 699.

[154] J. A. Palma, “Renal Dysfunction Might be a Marker of Cardiovascular Dysautonomia in Prodromal α-synucleinopathies,” Movement Disorders 35, no. 2 (2020): 374.

[155] Y. Qu, Q. X. Qin, D. L. Wang, et al., “Estimated Glomerular Filtration Rate Is a Biomarker of Cognitive Impairment in Parkinson's Disease,” Frontiers in Aging Neuroscience 15 (2023): 1130833.

[156] G. Maor, R. R. Dubreuil, and M. B. Feany, “α-Synuclein Promotes Neuronal Dysfunction and Death by Disrupting the Binding of Ankyrin to β-Spectrin,” Journal of Neuroscience 43, no. 9 (2023): 1614–1626.

[157] G. T. Corbett, Z. Wang, W. Hong, et al., “PrP Is a central Player in Toxicity Mediated by Soluble Aggregates of Neurodegeneration-causing Proteins,” Acta Neuropathologica 139, no. 3 (2020): 503–526.

[158] K. J. Gan and T. C. Südhof, “Specific Factors in Blood From Young but Not Old Mice Directly Promote Synapse Formation and NMDA-receptor Recruitment,” PNAS 116, no. 25 (2019): 12524–12533.

[159] A. Recasens and B. Dehay, “Alpha-synuclein Spreading in Parkinson's Disease,” Front Neuroanat 8 (2014): 159.

[160] J. Y. Jeong, H. J. Lee, N. Kim, et al., “Impaired Neuronal Activity as a Potential Factor Contributing to the Underdeveloped Cerebrovasculature in a Young Parkinson's disease Mouse Model,” Scientific Reports 13, no. 1 (2023): 22613.

[161] Z. Fan, Y. T. Pan, Z. Y. Zhang, et al., “Systemic Activation of NLRP3 Inflammasome and Plasma α-synuclein Levels Are Correlated With Motor Severity and Progression in Parkinson's Disease,” J Neuroinflammation 17, no. 1 (2020): 11.

[162] H. Scheiblich, L. Bousset, S. Schwartz, et al., “Microglial NLRP3 Inflammasome Activation Upon TLR2 and TLR5 Ligation by Distinct α-Synuclein Assemblies,” Journal of Immunology 207, no. 8 (2021): 2143–2154.

[163] P. La Vitola, C. Balducci, and M. Baroni, “Peripheral Inflammation Exacerbates α-synuclein Toxicity and Neuropathology in Parkinson's Models,” Neuropathology and Applied Neurobiology 47, no. 1 (2021): 43–60.

[164] K. Stoklund Dittlau and K. Freude, “Astrocytes: The Stars in Neurodegeneration?,” Biomolecules 14, no. 3 (2024): 289.

[165] S. Tullo, A. S. Miranda, E. Del Cid-Pellitero, et al., “Neuroanatomical and Cognitive Biomarkers of Alpha-synuclein Propagation in a Mouse Model of Synucleinopathy Prior to Onset of Motor Symptoms,” Journal of Neurochemistry 168, no. 8 (2024): 1546–1564.

[166] N. Y. Zhang, Z. Tang, and C. W. Liu, “alpha-Synuclein Protofibrils Inhibit 26 S Proteasome-mediated Protein Degradation: Understanding the Cytotoxicity of Protein Protofibrils in Neurodegenerative Disease Pathogenesis,” Journal of Biological Chemistry 283, no. 29 (2008): 20288–20298.

[167] K. Sneppen, L. Lizana, M. H. Jensen, et al., “Modeling Proteasome Dynamics in Parkinson's Disease,” Physical Biology 6, no. 3 (2009): 036005.

[168] C. W. Olanow and K. S. McNaught, “Ubiquitin-proteasome System and Parkinson's Disease,” Movement Disorders 21, no. 11 (2006): 1806–1823.

[169] Y. Liang, G. Zhong, M. Ren, et al., “The Role of Ubiquitin-Proteasome System and Mitophagy in the Pathogenesis of Parkinson's Disease,” Neuromolecular Med 25, no. 4 (2023): 471–488.

[170] V. Kumar, D. Singh, B. K. Singh, et al., “Alpha-synuclein Aggregation, Ubiquitin Proteasome System Impairment, and L-Dopa Response in Zinc-induced Parkinsonism: Resemblance to Sporadic Parkinson's Disease,” Molecular and Cellular Biochemistry 444, no. 1-2 (2018): 149–160.

[171] A. Kulkarni, K. Preeti, K. P. Tryphena, et al., “Proteostasis in Parkinson's Disease: Recent Development and Possible Implication in Diagnosis and Therapeutics,” Ageing Research Reviews 84 (2023): 101816.

[172] Y. Chu, H. Dodiya, P. Aebischer, et al., “Alterations in Lysosomal and Proteasomal Markers in Parkinson's disease: Relationship to Alpha-synuclein Inclusions,” Neurobiology of Disease 35, no. 3 (2009): 385–398.

[173] S. Sjödin, G. Brinkmalm, A. Öhrfelt, et al., “Endo-lysosomal Proteins and Ubiquitin CSF Concentrations in Alzheimer's and Parkinson's Disease,” Alzheimers Res Ther 11, no. 1 (2019): 82.

[174] S. Negi, N. Khurana, and N. Duggal, “The Misfolding Mystery: Α-synuclein and the Pathogenesis of Parkinson's Disease,” Neurochemistry International 177 (2024): 105760.

[175] R. Wang, J. Zhao, J. Zhang, et al., “Effect of Lysosomal and Ubiquitin-proteasome System Dysfunction on the Abnormal Aggregation of α-synuclein in PC12 Cells,” Exp Ther Med 9, no. 6 (2015): 2088–2094.

[176] H. J. Jang and K. C. Chung, “The Ubiquitin–proteasome System and Autophagy Mutually Interact in Neurotoxin-induced Dopaminergic Cell Death Models of Parkinson's Disease,” Febs Letters 596, no. 22 (2022): 2898–2913.

[177] S. Ray, N. Singh, R. Kumar, et al., “α-Synuclein Aggregation Nucleates Through Liquid-liquid Phase Separation,” Nature Chemistry 12, no. 8 (2020): 705–716.

[178] D. Ubbiali, M. Fratini, L. Piersimoni, et al., “Direct Observation of “Elongated” Conformational States in α-Synuclein Upon Liquid-Liquid Phase Separation,” Angewandte Chemie (International ed in English) 61, no. 46 (2022): e202205726.

[179] S. Alberti and A. A. Hyman, “Biomolecular Condensates at the Nexus of Cellular Stress, Protein Aggregation Disease and Ageing,” Nature Reviews Molecular Cell Biology 22, no. 3 (2021): 196–213.

[180] R. I. Morimoto, “The Heat Shock Response: Systems Biology of Proteotoxic Stress in Aging and Disease,” Cold Spring Harb Symp Quant Biol 76 (2011): 91–99.

[181] K. Hou, T. Liu, J. Li, et al., “Liquid-liquid Phase Separation Regulates Alpha-synuclein Aggregate and Mitophagy in Parkinson's Disease,” Frontiers in Neuroscience 17 (2023): 1250532.

[182] A. Patel, L. Malinovska, S. Saha, et al., “ATP as a Biological Hydrotrope,” Science 356, no. 6339 (2017): 753–756.

[183] A. S. Sawner, S. Ray, P. Yadav, et al., “Modulating α-Synuclein Liquid-Liquid Phase Separation,” Biochemistry 60, no. 48 (2021): 3676–3696.

[184] A. L. Mahul-Mellier, J. Burtscher, N. Maharjan, et al., “The Process of Lewy Body Formation, Rather Than Simply α-synuclein Fibrillization, Is One of the Major Drivers of Neurodegeneration,” PNAS 117, no. 9 (2020): 4971–4982.

[185] S. Maharana, J. Wang, D. K. Papadopoulos, et al., “RNA Buffers the Phase Separation Behavior of Prion-Like RNA Binding Proteins,” Science 360, no. 6391 (2018): 918–921.

[186] M. C. Epifane-de-Assunção, A. G. Bispo, Â. Ribeiro-Dos-Santos, et al., “Molecular Alterations in Core Subunits of Mitochondrial Complex I and Their Relation to Parkinson's Disease,” Molecular Neurobiology 62, no. 6 (2025): 6968–6982.

[187] D. Ramonet, C. Perier, A. Recasens, et al., “Optic Atrophy 1 Mediates Mitochondria Remodeling and Dopaminergic Neurodegeneration Linked to Complex I Deficiency,” Cell Death and Differentiation 20, no. 1 (2013): 77–85.

[188] A. H. V. Schapira, V. Mann, J. Cooper, et al., “Mitochondrial Function in Parkinson's Disease,” Annals of Neurology 32, no. 1 (1992): S116–S124.

[189] J. H. Shim, S. H. Yoon, K. H. Kim, et al., “The Antioxidant Trolox Helps Recovery From the Familial Parkinson's Disease-specific Mitochondrial Deficits Caused by PINK1- and DJ-1-deficiency in Dopaminergic Neuronal Cells,” Mitochondrion 11, no. 5 (2011): 707–715.

[190] V. K. Babu and N. Khurana, “A Review on Mitochondrial Dysfunction and Oxidative Stress due to Complex-I in Parkinson Disease,” Research Journal of Pharmacology and Pharmacodynamics 13, no. 4 (2021): 167–170.

[191] Z. Zhang, D. Wang, T. Sun, et al., “The SNARE Proteins SNAP25 and Synaptobrevin Are Involved in Endocytosis at Hippocampal Synapses,” Journal of Neuroscience 33, no. 21 (2013): 9169–9175.

[192] M. Kyoung, A. Srivastava, Y. Zhang, et al., “Kinetic Control of SNARE-Dependent Fusion by Accessory Factors and Calcium,” Biophysical Journal 100, no. 3 (2011): 90a.

[193] T.-I. Nishiki, K. Kuroki, T. Masumoto, et al. Ca2+ Sensors: Synaptotagmins. In: Mochida S, ed. Presynaptic Te. (Japan: Springer, 2015): 167–194.

[194] A. L. Zefirov and A. M. Petrov, “Lipids in the Processes of Exo- and Endocytosis of Synaptic Vesicles,” Neuroscience and Behavioral Physiology 42, no. 2 (2012): 144–152.

[195] J. C. Bridi and F. Hirth, “Mechanisms of α-Synuclein Induced Synaptopathy in Parkinson's Disease,” Frontiers in Neuroscience 12 (2018): 80.

[196] A. Cardinale, V. Calabrese, A. de Iure, et al., “Alpha-Synuclein as a Prominent Actor in the Inflammatory Synaptopathy of Parkinson's Disease,” International Journal of Molecular Sciences 22, no. 12 (2021): 6517.

[197] T. Inoshita, T. Arano, Y. Hosaka, et al., “Vps35 in Cooperation With LRRK2 Regulates Synaptic Vesicle Endocytosis Through the Endosomal Pathway in Drosophila,” Human Molecular Genetics 26, no. 15 (2017): 2933–2948.

[198] S. J. Orenstein, S. H. Kuo, I. Tasset, et al., “Interplay of LRRK2 With Chaperone-mediated Autophagy,” Nature Neuroscience 16, no. 4 (2013): 394–406.

[199] M. Niu, F. Zhao, K. Bondelid, et al., “VPS35 D620N knockin Mice Recapitulate Cardinal Features of Parkinson's Disease,” Aging Cell 20, no. 5 (2021): e13347.

[200] L. Fonseca-Ornelas, T. Viennet, M. Rovere, et al., “Altered Conformation of α-synuclein Drives Dysfunction of Synaptic Vesicles in a Synaptosomal Model of Parkinson's Disease,” Cell Reports 36, no. 1 (2021): 109333.

[201] K. Stokholm, M. B. Thomsen, J. A. Phan, et al., “α-Synuclein Overexpression Increases Dopamine D2/3 Receptor Binding and Immune Activation in a Model of Early Parkinson's Disease,” Biomedicines 9, no. 12 (2021): 1876.

[202] U. Scheller, C. Lee, P. Seibler, et al., “Impaired Neurogenesis and Synaptogenesis in iPSC-derived Parkinson's Patient Cortical Neurons With D620N VPS35 Mutation,” BioRxiv (2024), https://doi.org/10.1101/2024.08.07.606995. Preprint posted online August 7, 2024.

[203] W. Lu, T. Song, Z. Zang, et al., “Relaxometry Network Based on MRI R₂* Mapping Revealing Brain Iron Accumulation Patterns in Parkinson's Disease,” Neuroimage 303 (2024): 120943.

[204] B. A. Faucheux, M. E. Martin, C. Beaumont, et al., “Lack of Up-regulation of Ferritin Is Associated With Sustained Iron Regulatory Protein-1 Binding Activity in the Substantia nigra of Patients With Parkinson's Disease,” Journal of Neurochemistry 83, no. 2 (2002): 320–330.

[205] L. Ma, M. Gholam Azad, and M. Dharmasivam, “Parkinson's Disease: Alterations in Iron and Redox Biology as a Key to Unlock Therapeutic Strategies,” Redox Biology 41 (2021): 101896.

[206] M. Bi, X. Du, Q. Jiao, et al., “α-Synuclein Regulates Iron Homeostasis via Preventing Parkin-Mediated DMT1 Ubiquitylation in Parkinson's Disease Models,” Acs Chemical Neuroscience 11, no. 11 (2020): 1682–1691.

[207] X. Zeng, H. An, and F. Yu, “Benefits of Iron Chelators in the Treatment of Parkinson's Disease,” Neurochemical Research 46, no. 5 (2021): 1239–1251.

[208] Q. K. Lv, K. X. Tao, X. Y. Yao, et al., “Melatonin MT1 Receptors Regulate the Sirt1/Nrf2/Ho-1/Gpx4 Pathway to Prevent α-synuclein-induced Ferroptosis in Parkinson's Disease,” Journal of Pineal Research 76, no. 2 (2024): e12948.

[209] F. Tang, L. Y. Zhou, P. Li, et al., “Inhibition of ACSL4 Alleviates Parkinsonism Phenotypes by Reduction of Lipid Reactive Oxygen Species,” Neurotherapeutics 20, no. 4 (2023): 1154–1166.

[210] M. Merkel, B. Goebel, M. Boll, et al., “Mitochondrial Reactive Oxygen Species Formation Determines ACSL4/LPCAT2-Mediated Ferroptosis,” Antioxidants (Basel) 12, no. 8 (2023): 1590.

[211] Q. Q. Shen, X. H. Jv, X. Z. Ma, et al., “Cell Senescence Induced by Toxic Interaction Between α-synuclein and Iron Precedes Nigral Dopaminergic Neuron Loss in a Mouse Model of Parkinson's Disease,” Acta Pharmacologica Sinica 45, no. 2 (2024): 268–281.

[212] S. Romano, G. M. Savva, J. R. Bedarf, et al., “Meta-analysis of the Parkinson's Disease Gut Microbiome Suggests Alterations Linked to Intestinal Inflammation,” NPJ Parkinsons Dis 7, no. 1 (2021): 27.

[213] I. Choi, Y. Zhang, S. P. Seegobin, et al., “Microglia Clear Neuron-released α-synuclein via Selective Autophagy and Prevent Neurodegeneration,” Nature Communications 11, no. 1 (2020): 1386.

[214] C. B. Forsyth, K. M. Shannon, J. H. Kordower, et al., “Increased Intestinal Permeability Correlates With Sigmoid Mucosa Alpha-synuclein Staining and Endotoxin Exposure Markers in Early Parkinson's disease,” PLoS ONE 6, no. 12 (2011): e28032.

[215] Y. Zhao, V. R. Jaber, A. I. Pogue, et al., “Lipopolysaccharides (LPSs) as Potent Neurotoxic Glycolipids in Alzheimer's Disease (AD),” International Journal of Molecular Sciences 23, no. 20 (2022): 12671.

[216] H. Eo, S. Kim, U. J. Jung, et al., “Alpha-Synuclein and Microglia in Parkinson's Disease: From Pathogenesis to Therapeutic Prospects,” Journal of Clinical Medicine 13, no. 23 (2024): 7243.

[217] A. Heidari, N. Yazdanpanah, and N. Rezaei, “The Role of Toll-Like Receptors and Neuroinflammation in Parkinson's Disease,” J Neuroinflammation 19, no. 1 (2022): 135.

[218] Y. Li, Y. Xia, S. Yin, et al., “Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson's Disease,” Frontiers in Immunology 12 (2021): 719807.

[219] S. B. Suresh, A. Malireddi, M. Abera, et al., “Gut Microbiome and Its Role in Parkinson's Disease,” Cureus 16, no. 11 (2024): e73150.

[220] C. M. Qiao, W. Quan, Y. Zhou, et al., “Orally Induced High Serum Level of Trimethylamine N-oxide Worsened Glial Reaction and Neuroinflammation on MPTP-Induced Acute Parkinson's Disease Model Mice,” Molecular Neurobiology 60, no. 9 (2023): 5137–5154.

[221] R. Pitas, J. Boyles, S. Lee, et al., “Astrocytes Synthesize Apolipoprotein E and Metabolize Apolipoprotein E-containing Lipoproteins,” Biochimica Et Biophysica Acta 917, no. 1 (1987): 148–161.

[222] J. Ito, Y. Nagayasu, Y. Miura, et al., “Astrocyte׳s Endogenous apoE Generates HDL-Like Lipoproteins Using Previously Synthesized Cholesterol Through Interaction With ABCA1,” Brain Research 1570 (2014): 1–12.

[223] J. Chen, X. Zhang, H. Kusumo, et al., “Cholesterol Efflux Is Differentially Regulated in Neurons and Astrocytes: Implications for Brain Cholesterol Homeostasis,” Biochimica Et Biophysica Acta 1831, no. 2 (2013): 263–275.

[224] P. Zabrocki, I. Bastiaens, C. Delay, et al., “Phosphorylation, Lipid Raft Interaction and Traffic of Alpha-synuclein in a Yeast Model for Parkinson,” Biochimica Et Biophysica Acta 1783, no. 10 (2008): 1767–1780.

[225] T. Bartels, H. Zhang, K. Beyer, et al., “Plasmon Waveguide Resonance Shows Preferential Binding of Oligomeric Alpha-Synuclein to Raft-Like Lipid Mixtures,” Biophysical Journal 96, no. 3 (2009): 206a.

[226] A. Canerina-Amaro, D. Pereda, M. Díaz, et al., “Differential Aggregation and Phosphorylation of Alpha Synuclein in Membrane Compartments Associated with Parkinson Disease,” Frontiers in Neuroscience 13 (2019): 382.

[227] J. Newton, E. N. D. Palladino, C. Weigel, et al., “Targeting Defective Sphingosine Kinase 1 in Niemann-Pick Type C Disease With an Activator Mitigates Cholesterol Accumulation,” Journal of Biological Chemistry 295, no. 27 (2020): 9121–9133.

[228] T. S. Blom, M. D. Linder, K. Snow, et al., “Defective Endocytic Trafficking of NPC1 and NPC2 Underlying Infantile Niemann-Pick Type C Disease,” Human Molecular Genetics 12, no. 3 (2003): 257–272.

[229] A. Navarro-Romero, I. Fernández-González, J. Riera, et al., “Lysosomal Lipid Alterations Caused by Glucocerebrosidase Deficiency Promote Lysosomal Dysfunction, Chaperone-mediated-autophagy Deficiency, and Alpha-synuclein Pathology,” NPJ Parkinsons Dis 8, no. 1 (2022): 126.

[230] S. H. Kuo, I. Tasset, M. M. Cheng, et al., “Mutant Glucocerebrosidase Impairs α-synuclein Degradation by Blockade of Chaperone-mediated Autophagy,” Science Advances 8, no. 6 (2022): eabm6393.

[231] J. Magalhães, M. E. Gegg, A. Migdalska-Richards, et al., “Autophagic Lysosome Reformation Dysfunction in Glucocerebrosidase Deficient Cells: Relevance to Parkinson disease,” Human Molecular Genetics 25, no. 16 (2016): 3432–3445.

[232] L. Dai, L. Zou, L. Meng, et al., “Cholesterol Metabolism in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Targets,” Molecular Neurobiology 58, no. 5 (2021): 2183–2201.

[233] L. Dai, J. Wang, X. Zhang, et al., “27-Hydroxycholesterol Drives the Spread of α-Synuclein Pathology in Parkinson's Disease,” Movement Disorders 38, no. 11 (2023): 2005–2018.

[234] Y. Xia, G. Zhang, L. Kou, et al., “Reactive Microglia Enhance the Transmission of Exosomal Alpha-synuclein via Toll-Like Receptor 2,” Brain 144, no. 7 (2021): 2024–2037.

[235] A. Ascherio and M. A. Schwarzschild, “The Epidemiology of Parkinson's Disease: Risk Factors and Prevention,” Lancet Neurology 15, no. 12 (2016): 1257–1272.

[236] Y. Ben-Shlomo, S. Darweesh, J. Llibre-Guerra, et al., “The Epidemiology of Parkinson's Disease,” Lancet 403, no. 10423 (2024): 283–292.

[237] Y. Chen, X. Sun, Y. Lin, et al., “Non-Genetic Risk Factors for Parkinson's Disease: An Overview of 46 Systematic Reviews,” J Parkinsons Dis 11, no. 3 (2021): 919–935.

[238] O. Palin, C. Herd, K. E. Morrison, et al., “Systematic Review and Meta-analysis of Hydrocarbon Exposure and the Risk of Parkinson's Disease,” Parkinsonism & Related Disorders 21, no. 3 (2015): 243–248.

[239] X. Fang, D. Han, Q. Cheng, et al., “Association of Levels of Physical Activity with Risk of Parkinson Disease: A Systematic Review and Meta-analysis,” JAMA Network Open 1, no. 5 (2018): e182421.

[240] F. C. Bull, S. S. Al-Ansari, S. Biddle, et al., “World Health Organization 2020 Guidelines on Physical Activity and Sedentary Behaviour,” British Journal of Sports Medicine 54, no. 24 (2020): 1451–1462.

[241] C. Marras, C. G. Canning, and S. M. Goldman, “Environment, Lifestyle, and Parkinson's Disease: Implications for Prevention in the next Decade,” Movement Disorders 34, no. 6 (2019): 801–811.

[242] S. M. Goldman, K. Marek, R. Ottman, et al., “Concordance for Parkinson's Disease in Twins: A 20-year Update,” Annals of Neurology 85, no. 4 (2019): 600–605.

[243] V. Bellou, L. Belbasis, I. Tzoulaki, et al., “Environmental Risk Factors and Parkinson's Disease: An Umbrella Review of Meta-analyses,” Parkinsonism & Related Disorders 23 (2016): 1–9.

[244] M. Li, X. Zhang, K. Chen, et al., “Alcohol Exposure and Disease Associations: A Mendelian Randomization and Meta-Analysis on Weekly Consumption and Problematic Drinking,” Nutrients 16, no. 10 (2024): 1517.

[245] P. H. Allman, I. B. Aban, H. K. Tiwari, et al., “An Introduction to Mendelian Randomization With Applications in Neurology,” Mult Scler Relat Disord 24 (2018): 72–78.

[246] A. H. Evans, A. D. Lawrence, J. Potts, et al., “Relationship Between Impulsive Sensation Seeking Traits, Smoking, Alcohol and Caffeine Intake, and Parkinson's Disease,” Journal of Neurology, Neurosurgery, and Psychiatry 77, no. 3 (2006): 317–321.

[247] C. Xiang, S. Cong, X. Tan, et al., “A Meta-analysis of the Diagnostic Utility of Biomarkers in Cerebrospinal Fluid in Parkinson's Disease,” NPJ Parkinsons Dis 8, no. 1 (2022): 165.

[248] H. Theis, N. Pavese, I. Rektorová, et al., “Imaging Biomarkers in Prodromal and Earliest Phases of Parkinson's Disease,” J Parkinsons Dis 14, no. s2 (2024): S353–S365.

[249] S. K. Meles, W. H. Oertel, and K. L. Leenders, “Circuit Imaging Biomarkers in Preclinical and Prodromal Parkinson's Disease,” Molecular Medicine 27, no. 1 (2021): 111.

[250] G. F. Crotty, S. J. Ayer, and M. A. Schwarzschild, “Designing the First Trials for Parkinson's Prevention,” J Parkinsons Dis 14, no. s2 (2024): S381–S393.

[251] H. Chohan, K. Senkevich, R. K. Patel, et al., “Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression,” Movement Disorders 36, no. 6 (2021): 1420–1429.

[252] K. O. Kopp, E. J. Glotfelty, Y. Li, et al., “Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Neuroinflammation: Implications for Neurodegenerative Disease Treatment,” Pharmacological Research 186 (2022): 106550.

[253] D. G. Standaert, “GLP-1, Parkinson's Disease, and Neuroprotection,” New England Journal of Medicine 390, no. 13 (2024): 1233–1234.

[254] K. Kalinderi, V. Papaliagkas, and L. Fidani, “GLP-1 Receptor Agonists: A New Treatment in Parkinson's Disease,” International Journal of Molecular Sciences 25, no. 7 (2024): 3812.

[255] C. A. Mulvaney, G. S. Duarte, J. Handley, et al., “GLP-1 Receptor Agonists for Parkinson's Disease,” Cochrane Database of Systematic Reviews (Online) 7, no. 7 (2020): CD012990.

[256] D. Athauda, K. Maclagan, S. S. Skene, et al., “Exenatide Once Weekly versus Placebo in Parkinson's Disease: A Randomised, Double-blind, Placebo-controlled Trial,” Lancet 390, no. 10103 (2017): 1664–1675.

[257] H. F. Yan, T. Zou, Q. Z. Tuo, et al., “Ferroptosis: Mechanisms and Links With Diseases,” Signal Transduct Target Ther 6, no. 1 (2021): 49.

[258] R. J. Ward, F. A. Zucca, J. H. Duyn, et al., “The Role of Iron in Brain Ageing and Neurodegenerative Disorders,” Lancet Neurology 13, no. 10 (2014): 1045–1060.

[259] A. Martin-Bastida, R. J. Ward, R. Newbould, et al., “Brain Iron Chelation by deferiprone in a Phase 2 Randomised Double-blinded Placebo Controlled Clinical Trial in Parkinson's Disease,” Scientific Reports 7, no. 1 (2017): 1398.

[260] A. M. Badawoud, L. S. Ali, M. S. Abdallah, et al., “The Relation Between Parkinson's Disease and Non-steroidal Anti-inflammatories; a Systematic Review and Meta-analysis,” Frontiers in pharmacology 15 (2024): 1434512.

[261] J. J. Gagne and M. C. Power, “Anti-inflammatory Drugs and Risk of Parkinson Disease: A Meta-analysis,” Neurology 74, no. 12 (2010): 995–1002.

[262] S. Fahn, D. Oakes, I. Shoulson, et al., “Levodopa and the Progression of Parkinson's Disease,” New England Journal of Medicine 351, no. 24 (2004): 2498–2508.

[263] F. C. Church, “Treatment Options for Motor and Non-Motor Symptoms of Parkinson's Disease,” Biomolecules 11, no. 4 (2021): 612.

[264] M. K. Y. Mak, I. S. K. Wong-Yu, R. T. H. Cheung, et al., “Effectiveness of Balance Exercise and Brisk Walking on Alleviating Nonmotor and Motor Symptoms in People with Mild-to-Moderate Parkinson Disease: A Randomized Clinical Trial with 6-Month Follow-up,” Archives of Physical Medicine and Rehabilitation 105, no. 10 (2024): 1890–1899.

[265] X. Zhou, P. Zhao, X. Guo, et al., “Effectiveness of Aerobic and Resistance Training on the Motor Symptoms in Parkinson's disease: Systematic Review and Network Meta-analysis,” Frontiers in Aging Neuroscience 14 (2022): 935176.

[266] M. M. Reich, J. Hsu, M. Ferguson, et al., “A Brain Network for Deep Brain Stimulation Induced Cognitive Decline in Parkinson's Disease,” Brain 145, no. 4 (2022): 1410–1421.

[267] R. G. Cury and C. França, “Tailoring and Personalizing Deep Brain Stimulation for Parkinson's Disease,” Arquivos De Neuro-Psiquiatria 82, no. 4 (2024): 1–2.

[268] K. C. Sonntag, B. Song, N. Lee, et al., “Pluripotent Stem Cell-based Therapy for Parkinson's Disease: Current Status and Future Prospects,” Progress in Neurobiology 168 (2018): 1–20.

[269] A. Kirkeby, J. Nelander, D. B. Hoban, et al., “Preclinical Quality, Safety, and Efficacy of a human Embryonic Stem Cell-derived Product for the Treatment of Parkinson's Disease, STEM-PD,” Cell Stem Cell 30, no. 10 (2023): 1299–1314. e9.

[270] T. Stoddard-Bennett and R. Reijo Pera, “Treatment of Parkinson's Disease Through Personalized Medicine and Induced Pluripotent Stem Cells,” Cells 8, no. 1 (2019): 26.

[271] A. Morizane, “[Cell therapy for Parkinson's disease With induced pluripotent stem cells],” Rinsho Shinkeigaku Clinical Neurology 59, no. 3 (2019): 119–124.

[272] F. Wang, Z. Sun, D. Peng, et al., “Cell-therapy for Parkinson's Disease: A Systematic Review and Meta-analysis,” Journal of Translational Medicine 21, no. 1 (2023): 601.

[273] Y. Cheng, G. Tan, Q. Zhu, et al., “Efficacy of Fecal Microbiota Transplantation in Patients With Parkinson's Disease: Clinical Trial Results From a Randomized, Placebo-controlled Design,” Gut Microbes 15, no. 2 (2023): 2284247.

[274] S. G. Sorboni, H. S. Moghaddam, R. Jafarzadeh-Esfehani, et al., “A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders,” Clinical Microbiology Reviews 35, no. 1 (2022): e0033820.

[275] A. Varesi, L. I. M. Campagnoli, F. Fahmideh, et al., “The Interplay Between Gut Microbiota and Parkinson's Disease: Implications on Diagnosis and Treatment,” International Journal of Molecular Sciences 23, no. 20 (2022): 12289.

[276] Z. Zhao, J. Ning, X. Q. Bao, et al., “Fecal Microbiota Transplantation Protects Rotenone-induced Parkinson's disease Mice via Suppressing Inflammation Mediated by the Lipopolysaccharide-TLR4 Signaling Pathway Through the Microbiota-gut-brain Axis,” Microbiome 9, no. 1 (2021): 226.

[277] C. Zhuo, X. Zhu, R. Jiang, et al., “Comparison for Efficacy and Tolerability Among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis,” Scientific Reports 8 (2017): 45865.

[278] D. Nemade, T. Subramanian, and V. Shivkumar, “An Update on Medical and Surgical Treatments of Parkinson's Disease,” Aging Dis 12, no. 4 (2021): 1021–1035.

[279] T. B. Stoker, K. M. Torsney, and R. A. Barker, “Emerging Treatment Approaches for Parkinson's Disease,” Frontiers in Neuroscience 12 (2018): 693.

[280] A. Elkouzi, V. Vedam-Mai, R. S. Eisinger, et al., “Emerging Therapies in Parkinson Disease—repurposed Drugs and New Approaches,” Nature Reviews Neurology 15, no. 4 (2019): 204–223.

[281] H. Feng, C. Li, J. Liu, et al., “Virtual Reality Rehabilitation versus Conventional Physical Therapy for Improving Balance and Gait in Parkinson's Disease Patients: A Randomized Controlled Trial,” Medical Science Monitor 25 (2019): 4186–4192.

[282] A. Bruggeman, C. Vandendriessche, H. Hamerlinck, et al., “Safety and Efficacy of Faecal Microbiota Transplantation in Patients With Mild to Moderate Parkinson's Disease (GUT-PARFECT): A Double-blind, Placebo-controlled, Randomised, Phase 2 Trial,” EClinicalMedicine 71 (2024): 102563.

[283] J. E. Parker, A. Martinez, G. K. Deutsch, et al., “Safety of Plasma Infusions in Parkinson's Disease,” Movement Disorders 35, no. 11 (2020): 1905–1913.

[284] L. Katsimpardi, N. K. Litterman, P. A. Schein, et al., “Vascular and Neurogenic Rejuvenation of the Aging Mouse Brain by Young Systemic Factors,” Science 344, no. 6184 (2014): 630–634.

[285] E. Anitua, C. Pascual, R. Pérez-Gonzalez, et al., “Intranasal PRGF-Endoret Enhances Neuronal Survival and Attenuates NF-κB-dependent Inflammation Process in a Mouse Model of Parkinson's Disease,” J Control Release 203 (2015): 170–180.

[286] M. L. Herrera, L. G. Champarini, O. M. Basmadjian, et al., “IGF-1 Gene Therapy Prevents Spatial Memory Deficits and Modulates Dopaminergic Neurodegeneration and Inflammation in a Parkinsonism Model,” Brain, Behavior, and Immunity 119 (2024): 851–866.

[287] S. Y. Romero-Zerbo, N. Valverde, and S. Claros, “New Molecular Mechanisms to Explain the Neuroprotective Effects of Insulin-Like Growth Factor II in a Cellular Model of Parkinson's Disease,” Journal of Advanced Research 67 (2025): 349–359.

[288] M. A. Sheikh, Y. S. Malik, Z. Xing, et al., “Polylysine-modified Polyethylenimine (PEI-PLL) Mediated VEGF Gene Delivery Protects Dopaminergic Neurons in Cell Culture and in Rat Models of Parkinson's Disease (PD),” Acta Biomaterialia 54 (2017): 58–68.

[289] L. Gu, P. Zhang, W. Zuo, et al., “Association Between Serum IGF‑1 Levels and Non-motor Symptoms in Parkinson's Disease,” Neurol Sci 46, no. 3 (2025): 1201–1206.

[290] P. Gątarek, J. Sekulska-Nalewajko, B. Bobrowska-Korczaka, et al., “Plasma Metabolic Disturbances in Parkinson's Disease Patients,” Biomedicines 10, no. 12 (2022): 3005.

[291] G. Edgren, H. Hjalgrim, K. Rostgaard, et al., “Transmission of Neurodegenerative Disorders through Blood Transfusion: A Cohort Study,” Annals of Internal Medicine 165, no. 5 (2016): 316–324.

[292] M. Posavi, M. Diaz-Ortiz, B. Liu, et al., “Characterization of Parkinson's Disease Using Blood-based Biomarkers: A Multicohort Proteomic Analysis,” Plos Medicine 16, no. 10 (2019): e1002931.

[293] P. Youssef, W. S. Kim, G. M. Halliday, et al., “Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson's Disease Patients,” J Parkinsons Dis 11, no. 4 (2021): 1761–1772.

[294] X. Hong, Y. Zheng, J. Hou, et al., “Detection of Elevated Levels of PINK1 in Plasma From Patients With Idiopathic Parkinson's Disease,” Frontiers in Aging Neuroscience 16 (2024): 1369014.

[295] A. Gleason, N. Tayebi, G. Lopez, et al., “No Evidence That Glucosylsphingosine Is a Biomarker for Parkinson's Disease: Statistical Differences Do Not Necessarily Indicate Biological Significance,” Movement Disorders 37, no. 3 (2022): 653.

[296] J. X. Shi and K. Z. Zhang, “Advancements in Autologous Stem Cell Transplantation for Parkinson's Disease,” Curr Stem Cell Res Ther 19, no. 10 (2024): 1321–1327.

[297] R. Rydbirk, B. Elfving, M. D. Andersen, et al., “Cytokine Profiling in the Prefrontal Cortex of Parkinson's Disease and Multiple System Atrophy Patients,” Neurobiology of Disease 106 (2017): 269–278.

[298] R. S. Monteiro-Junior, T. Cevada, and B. R. Oliveira, “We Need to Move More: Neurobiological Hypotheses of Physical Exercise as a Treatment for Parkinson's Disease,” Medical Hypotheses 85, no. 5 (2015): 537–541.

[299] O. Bondarenko and M. Saarma, “Neurotrophic Factors in Parkinson's Disease: Clinical Trials, Open Challenges and Nanoparticle-Mediated Delivery to the Brain,” Front Cell Neurosci 15 (2021): 682597.

[300] C. H. Fan, C. Y. Ting, C. Y. Lin, et al., “Noninvasive, Targeted, and Non-Viral Ultrasound-Mediated GDNF-Plasmid Delivery for Treatment of Parkinson's Disease,” Scientific Reports 6 (2016): 19579.

[301] A. C. Williams, M. L. Smith, R. H. Waring, et al., “Idiopathic Parkinson's Disease: A Genetic and Environmental Model,” Advances in Neurology 80 (1999): 215–218.

[302] X. Wang and L. M. Cheng, “[Application of EXODUS system combined With allosteric DNA nanoswitches in the detection of miR-107 Among plasma exosomes of Parkinson's disease patients],” Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine] 58, no. 8 (2024): 1191–1196.

[303] D. G. Kulabukhova, L. A. Garaeva, A. K. Emelyanov, et al., “[Plasma Exosomes in Inherited Forms of Parkinson's Disease],” Molekuliarnaia Biologiia 55, no. 2 (2021): 338–345.

[304] E. T. Ebert, K. M. Schwinghamer, and T. J. Siahaan, “Delivery of Neuroregenerative Proteins to the Brain for Treatments of Neurodegenerative Brain Diseases,” Life (Basel) 14, no. 11 (2024): 1456.

[305] H. Park and K. A. Chang, “Therapeutic Potential of Repeated Intravenous Transplantation of Human Adipose-Derived Stem Cells in Subchronic MPTP-Induced Parkinson's Disease Mouse Model,” International Journal of Molecular Sciences 21, no. 21 (2020): 8129.

[306] D. Sepúlveda, F. Grunenwald, A. Vidal, et al., “Insulin-Like Growth Factor 2 and Autophagy Gene Expression Alteration Arise as Potential Biomarkers in Parkinson's Disease,” Scientific Reports 12, no. 1 (2022): 2038.

[307] C. Y. Lin, Y. C. Lin, C. Y. Huang, et al., “Ultrasound-responsive Neurotrophic Factor-loaded Microbubble- liposome Complex: Preclinical Investigation for Parkinson's Disease Treatment,” J Control Release 321 (2020): 519–528.

[308] A. Stefani, M. Pierantozzi, S. Cardarelli, et al., “Neurotrophins as Therapeutic Agents for Parkinson's Disease; New Chances from Focused Ultrasound?,” Frontiers in Neuroscience 16 (2022): 846681.

[309] X. Yu, M. Persillet, L. Zhang, et al., “Evaluation of Blood Flow as a Route for Propagation in Experimental Synucleinopathy,” Neurobiology of Disease 150 (2021): 105255.

[310] X. Ma, L. Chen, N. Song, et al., “Blood-Derived α-Synuclein Aggregated in the Substantia Nigra of Parabiotic Mice,” Biomolecules 11, no. 9 (2021): 1287.

[311] Y. Wang, T. K. Ulland, J. D. Ulrich, et al., “TREM2-mediated Early Microglial Response Limits Diffusion and Toxicity of Amyloid Plaques,” Journal of Experimental Medicine 213, no. 5 (2016): 667–675.

[312] X. L. Bu, Y. Xiang, and W. S. Jin, “Blood-derived Amyloid-β Protein Induces Alzheimer's Disease Pathologies,” Molecular Psychiatry 23, no. 9 (2018): 1948–1956.

[313] A. Heyman, W. E. Wilkinson, J. A. Stafford, et al., “Alzheimer's Disease: A Study of Epidemiological Aspects,” Annals of Neurology 15, no. 4 (1984): 335–341.

[314] L. A. Amaducci, L. Fratiglioni, W. A. Rocca, et al., “Risk Factors for Clinically Diagnosed Alzheimer's Disease: A Case-control Study of an Italian Population,” Neurology 36, no. 7 (1986): 922–931.

[315] G. A. Broe, A. S. Henderson, H. Creasey, et al., “A Case-control Study of Alzheimer's Disease in Australia,” Neurology 40, no. 11 (1990): 1698–1707.

[316] N. I. Bohnen, M. A. Warner, E. Kokmen, et al., “Prior Blood Transfusions and Alzheimer's Disease,” Neurology 44, no. 6 (1994): 1159–1160.

[317] E. S. O'Meara, W. A. Kukull, G. D. Schellenberg, et al., “Alzheimer's Disease and History of Blood Transfusion by Apolipoprotein-E Genotype,” Neuroepidemiology 16, no. 2 (1997): 86–93.

[318] F. Scheperjans, R. Levo, B. Bosch, et al., “Fecal Microbiota Transplantation for Treatment of Parkinson Disease: A Randomized Clinical Trial,” JAMA Neurology 81, no. 9 (2024): 925–938.

[319] J. Sun, H. Li, and Y. Jin, “Probiotic Clostridium Butyricum Ameliorated Motor Deficits in a Mouse Model of Parkinson's Disease via Gut Microbiota-GLP-1 Pathway,” Brain, Behavior, and Immunity 91 (2021): 703–715.

[320] M. De Sciscio, R. V. Bryant, S. Haylock-Jacobs, et al., “Faecal Microbiota Transplant in Parkinson's disease: Pilot Study to Establish Safety & Tolerability,” NPJ Parkinsons Dis 11, no. 1 (2025): 203.

[321] B. Aktas, B. Aslim, and D. A. Ozdemir, “A Neurotherapeutic Approach With Lacticaseibacillus Rhamnosus E9 on Gut Microbiota and Intestinal Barrier in MPTP-induced Mouse Model of Parkinson's Disease,” Scientific Reports 14, no. 1 (2024): 15460.

[322] S. J. Ott, G. H. Waetzig, A. Rehman, et al., “Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients with Clostridium difficile Infection,” Gastroenterology 152, no. 4 (2017): 799–811. e7.

[323] T. S. Rasmussen, A. K. Koefoed, R. R. Jakobsen, et al., “Bacteriophage-mediated Manipulation of the Gut Microbiome—promises and Presents Limitations,” Fems Microbiology Review 44, no. 4 (2020): 507–521.

[324] C. Marcella, B. Cui, C. R. Kelly, et al., “Systematic Review: The Global Incidence of Faecal Microbiota Transplantation-related Adverse Events From 2000 to 2020,” Alimentary Pharmacology & Therapeutics 53, no. 1 (2021): 33–42.

[325] M. F. Sun, Y. L. Zhu, Z. L. Zhou, et al., “Neuroprotective Effects of Fecal Microbiota Transplantation on MPTP-induced Parkinson's disease Mice: Gut Microbiota, Glial Reaction and TLR4/TNF-α Signaling Pathway,” Brain, Behavior, and Immunity 70 (2018): 48–60.

[326] X. Fang, S. Liu, B. Muhammad, et al., “Gut Microbiota Dysbiosis Contributes to α-synuclein-related Pathology Associated With C/EBPβ/AEP Signaling Activation in a Mouse Model of Parkinson's disease,” Neural Regen Res 19, no. 9 (2024): 2081–2088.

[327] H. Huang, H. Xu, Q. Luo, et al., “Fecal Microbiota Transplantation to Treat Parkinson's Disease With Constipation: A Case Report,” Medicine 98, no. 26 (2019): e16163.

[328] X. Y. Kuai, X. H. Yao, L. J. Xu, et al., “Evaluation of Fecal Microbiota Transplantation in Parkinson's disease Patients With Constipation,” Microbial Cell Factories 20, no. 1 (2021): 98.

[329] L. Xue, L. Wang, Z. Ou, et al., “Clinical Efficacy of Fecal Microbiota Transplantation in Treatment of Parkinson′s Disease With Constipation,” Chin J Neurol 52, no. 12 (2019): 1054–1058.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.